An international, multi-institution survey of the use of EUS in the diagnosis of pancreatic cystic lesions

Guo, Nan; Brugge, William R.; Saxena, Payal; Sahai, Anand V.; Adler, Douglas G.; Giovannini, Marc; Pausawasdi, Nonthalee; Santo, Erwin; Mishra, Girish; Tam, William; Kida, Mitsuhiro; Mora-Levy, José Guillermo de la; Sharma, Malay; Umar, Muhammad; Katanuma, Akio; Lee, Linda; Garg, Pramod Kumar; Eloubeidi, Mohamad A.; Yu, Ho Khek; Raijman, Isaac; Arias, Brenda Lucía Arturo; Bhutani, Manoop S.; Carrara, Sandro; Rai, Praveer; Mukai, Shuntaro; Palazzo, Laurent; Dietrich, Christoph F.; Nguyen, Nam Q.; Nady, Mohamed M. El; Poley, Jan Werner; Guaraldi, Simone; Kalaitzakis, Evangelos; Sabbagh, Luis; Lariño‐Noia, José; Gress, Frank G.; Lee, Yuk-Tong; Rana, Surinder Singh; Fusaroli, Pietro; Hocke, Michael; Dhir, Vinay; Lakhtakia, Sundeep; Ratanachu‐ek, Thawee; Rao, A S Chalapathi; Vilmann, Peter; Okasha, Hussein Hassan; Irisawa, Atsushi; Ponnudurai, Ryan; Leong, Ang Tiing; Artifon, Everson L.; Iglesias‐García, Julio; Săftoiu, Adrian; Larghi, Alberto; Robles-Medranda, Carlos; Sun, Siyu

doi:10.4103/eus.eus_61_19

Cited by 10 publications

(4 citation statements)

References 44 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a through-the-needle microforceps device was developed for EUS-guided tissue sampling of pancreas cystic lesions [ 39 ]. These microforceps can be advanced through the lumen of a standard 19-gauge EUS-FNA needle for through-the-needle tissue biopsy (TTNB) of pancreas cystic lesions [ 40 , 41 ]. EUS-TTNB is a useful tool for the differential diagnosis of pancreatic cystic lesions.…”

Section: Eus-fna Of the Gallbladdermentioning

confidence: 99%

The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions

Hijioka¹,

Nagashio²,

Ohba³

et al. 2021

Diagnostics

View full text Add to dashboard Cite

Endoscopic ultrasonography (EUS) has greater spatial resolution than other diagnostic imaging modalities. In addition, if gallbladder lesions are found and gallbladder cancer is suspected, EUS is an indispensable modality, enabling detailed tests for invasion depth evaluation using the Doppler mode and ultrasound agents. Furthermore, for gallbladder lesions, EUS fine-needle aspiration (EUS-FNA) can be used to differentiate benign and malignant forms of conditions, such as xanthogranulomatous cholecystitis, and collect evidence before chemotherapy. EUS-FNA is also useful for highly precise and specific diagnoses. However, the prevention of bile leakage, an accidental symptom, is highly important. Advancements in next-generation sequencing (NGS) technologies facilitate the application of multiple parallel sequencing to EUS-FNA samples. Several biomarkers are expected to stratify treatment for gallbladder cancer; however, NGS can unveil potential predictive genomic biomarkers for the treatment response. It is believed that NGS may be feasible with samples obtained using EUS-FNA, further increasing the demand for EUS-FNA.

show abstract

Section: Eus-fna Of the Gallbladdermentioning

confidence: 99%

The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions

Hijioka¹,

Nagashio²,

Ohba³

et al. 2021

Diagnostics

View full text Add to dashboard Cite

show abstract

“…With curved-linear echoendoscopes even minute details of the pancreatic duct can be delineated and if adequate, sampled for cyto- or even histopath-ology. Without manipulating the papilla and the pancreatic duct,contrast-enhanced EUS[ 248 249 250 251 252 ] or elastography[ 253 255 256 257 258 259 ] are possible. The stiffness of miniprobes that makes it problematic to follow the angulated main duct prevents most endoscopists from performing IDUS of the pancreas.…”

Section: Pancreatic Disordersmentioning

confidence: 99%

Controversies in EUS: Do we need miniprobes?

et al. 2021

Self Cite

View full text Add to dashboard Cite

This is the fifth in a series of papers entitled “Controversies in EUS.” In the current paper, we deal with high-resolution catheter probes, otherwise known as EUS miniprobes (EUS-MPs). The application of miniprobes for early carcinomas in the entire intestinal tract, for subepithelial lesions, and for findings in the bile duct and pancreatic duct as well as endobronchial use is critically discussed. Submucous lesions, especially in the colon, but also early carcinomas in special cases are considered the most important indications. The argument is illustrated by numerous examples.

show abstract

“…At present, surgical resection is the primary treatment method for pancreatic cancer; however, only 15%-20% of patients are eligible for surgical resection because of late diagnosis[ 7 ]. In recent years, with the development of endoscopic ultrasonography and pathology, early diagnosis of pancreatic cancer has been improved[ 8 - 10 ]; however, there are still only few cases that can be surgically removed. Moreover, pancreatic cancer has a strong tendency to metastasize and a high recurrence rate following surgery.…”

Section: Introductionmentioning

confidence: 99%

Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway

Li¹,

Yang²,

Liu³

et al. 2021

WJGO

Self Cite

View full text Add to dashboard Cite

BACKGROUND Pancreatic cancer is a highly malignant tumor of the gastrointestinal system whose emerging resistance to chemotherapy has necessitated the development of novel antitumor treatments. Scoparone, a traditional Chinese medicine monomer with a wide range of pharmacological properties, has attracted considerable attention for its antitumor activity. AIM To explore the potential antitumor effect of scoparone on pancreatic cancer and the possible molecular mechanism of action. METHODS The target genes of scoparone were determined using both the bioinformatics and multiplatform analyses. The effect of scoparone on pancreatic cancer cell proliferation, migration, invasion, cell cycle, and apoptosis was detected in vitro . The expression of hub genes was tested using quantitative reverse transcription polymerase chain reaction (qRT-PCR), and the molecular mechanism was analyzed using Western blot. The in vivo effect of scoparone on pancreatic cancer cell proliferation was detected using a xenograft tumor model in nude mice as well as immunohistochemistry. RESULTS The hub genes involved in the suppression of pancreatic cancer by scoparone were obtained by network bioinformatics analyses using publicly available databases and platforms, including SwissTargetPrediction, STITCH, GeneCards, CTD, STRING, WebGestalt, Cytoscape, and Gepia; AKT1 was confirmed using qRT-PCR to be the hub gene. Cell Counting Kit-8 assay revealed that the viability of Capan-2 and SW1990 cells was significantly reduced by scoparone treatment exhibiting IC 50 values of 225.2 μmol/L and 209.1 μmol/L, respectively. Wound healing and transwell assays showed that scoparone inhibited the migration and invasion of pancreatic cancer cells. Additionally, flow cytometry confirmed that scoparone caused cell cycle arrest and induced apoptosis. Scoparone also increased the expression levels of Bax and cleaved caspase-3, decreased the levels of MMP9 and Bcl-2, and suppressed the phosphorylation of Akt without affecting total PI3K and Akt. Moreover, compared with the control group, xenograft tumors, in the 200 μmol/L scoparone treatment group, were smaller in volume and lighter in weight, and the percentages of Ki65- and PCNA-positive cells were decreased. CONCLUSION Our findings indicate that scoparone inhibits pancreatic cancer cell proliferation in vitro and in vivo , inhibits migration and invasion, and induces cycle arrest and apoptosis in vitro through the PI3K/Akt signaling pathway.

show abstract

An international, multi-institution survey of the use of EUS in the diagnosis of pancreatic cystic lesions

Cited by 10 publications

References 44 publications

The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions

The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions

Controversies in EUS: Do we need miniprobes?

Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway

Contact Info

Product

Resources

About